Additional early-stage research and drug discovery news in brief, from: AB Science, Capsida Biotherapeutics, Channel Therapeutics, Excision Biotherapeutics, In8bio, Precision Biosciences.
The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated:
Halda Therapeutics LLC has synthesized heterobifunctional compounds able to bind both androgen receptor and bromodomain-containing protein 4 (BRD4; HUNK1) reported to be useful for the treatment of cancer.
ADC Therapeutics SA has described antibody-drug conjugates comprising antibody targeting sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi-2b) covalently linked to exatecan through a linker reported to be useful for the treatment of ovarian cancer and non-small-cell lung cancer (NSCLC).
Gen1e Lifesciences Inc. has disclosed drugs targeting extracellular-regulated kinase (ERK) reported to be useful for the treatment of cancer, inflammatory disorders, autoimmune and lung diseases.
Starg (Wuhan) Pharmaceutical Technology Co. Ltd. has discovered compounds acting as diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer.
Hepatocellular carcinoma (HCC), which accounts for up to 80% of cases of primary liver cancer, is typically diagnosed in an advanced stage, meaning a poor prognosis. Understanding what drives progression may help identify proteins and pathways that can be targeted to slow down the disease.
Acute myeloid leukemia (AML) harboring KMT2A rearrangements (KMT2A-r) represents a highly aggressive disease subtype, characterized by poor therapeutic response and a high risk of relapse.